Neurogene Inc. Stock Issued During Period, Value, Purchase of Assets
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Neurogene Inc. stock issued during period, value, purchase of assets for the quarter ending 2019-12-31 was $0.00.
- Neurogene Inc. stock issued during period, value, purchase of assets for the quarter ending 2019-09-30 was $15.05M.
- Neurogene Inc. stock issued during period, value, purchase of assets for fiscal 2019 was $15.05M.
| Period end | Stock Issued During Period, Value, Purchase of Assets 3 month | Stock Issued During Period, Value, Purchase of Assets 12 month |
|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $15.05M 10-K · filed 2021-03-25 |
| 2019-09-30 | $15.05M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |